Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Conmed (CNMD) to $68 from $80 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 results that beat on both the top and bottom lines. Management narrowed the range on its revenue guide but, encouragingly, raised its adjusted EPS guidance. Piper views the revenue guide as further conservatism from management as they continue their top-line turnaround efforts.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNMD: